The Tri-Institutional Therapeutics Discovery Institute is speeding early-stage drug development through an innovative collaboration between academia and industry.
Dr. Holly Prigerson wins a 2015 Outstanding Investigator Award from the National Cancer Institute and other awards, honors, prizes and achievements for the week of Nov.13 - Nov. 20.
A powerful new test that can reveal untapped therapies for patients with advanced cancers by scanning thousands of their genes will soon be available for patients at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.
Weill Cornell Medicine has entered into an agreement with Top Spring Huaxia Medical Investment Co. Ltd. to help it develop a modern outpatient diagnostic clinic in China.
One of the most commonly used general anesthetics induces unconsciousness in part by reducing the amount of calcium ion that flows into nerve cells and triggers chemical communication between them.
A non-invasive and quick lung function test frequently used to evaluate whether or not a smoker is at risk for developing pulmonary disease is likely mislabeling a significant percentage of smokers as healthy.
While a new study has found that increased physician spending in a hospital setting results in fewer malpractice claims, more research needs to be done before the medical community reacts.
A new therapeutic approach that targets an aggressive form of lymphoma may greatly increase the efficacy of treatment and result in better outcomes for patients.
NewYork-Presbyterian, with Weill Cornell Medicine, has officially opened the NewYork-Presbyterian/Lower Manhattan Cancer Center, a freestanding, state-of-the-art radiation oncology center located on 21 West Broadway in Manhattan.
